Study of a PD-1 Inhibitor (JTX-4014) in Subjects With Solid Tumor Malignancies
Status:
Active, not recruiting
Trial end date:
2022-08-01
Target enrollment:
Participant gender:
Summary
JTX-4014-101 is a Phase 1, open label, dose escalation clinical study of JTX-4014 in adult
subjects with advanced refractory solid tumor malignancies, to determine the maximum
tolerated dose (MTD) and recommended Phase 2 dose (RP2D).